Online inquiry

IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12778MR)

This product GTTS-WQ12778MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets NOTCH1 gene. The antibody can be applied in Lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_017617.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4851
UniProt ID P46531
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12778MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4065MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ3146MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ7453MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ6524MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ7225MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ12336MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ5513MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ7065MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW